We Offer Worldwide Shipping
Login Wishlist

Timosaponin A1

$173

  • Brand : BIOFRON

  • Catalogue Number : BD-P0050

  • Specification : 94.0%(HPLC)

  • CAS number : 68422-00-4

  • Formula : C33H54O8

  • Molecular Weight : 578.78

  • PUBCHEM ID : 71767755

  • Volume : 10mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0050

Analysis Method

HPLC,NMR,MS

Specification

94.0%(HPLC)

Storage

2-8°C

Molecular Weight

578.78

Appearance

Powder

Botanical Source

dried rhizomes of Anemarrhena asphodeloides

Structure Type

Steroids

Category

SMILES

CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CCC(C6)OC7C(C(C(C(O7)CO)O)O)O)C)C)C)OC1

Synonyms

(2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-[(1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S,16S,18R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl]oxyoxane-3,4,5-triol

IUPAC Name

(2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-[(1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S,16S,18R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl]oxyoxane-3,4,5-triol

Applications

Density

1.3±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

374.4±31.5 °C

Boiling Point

695.5±55.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C33H54O8/c1-17-7-12-33(38-16-17)18(2)26-24(41-33)14-23-21-6-5-19-13-20(8-10-31(19,3)22(21)9-11-32(23,26)4)39-30-29(37)28(36)27(35)25(15-34)40-30/h17-30,34-37H,5-16H2,1-4H3/t17-,18-,19+,20-,21+,22-,23-,24-,25+,26-,27-,28-,29+,30+,31-,32-,33+/m0/s1

InChl Key

ZNEIIZNXGCIAAL-MYNIFUFOSA-N

WGK Germany

RID/ADR

HS Code Reference

2938900000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:68422-00-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

26516362

Abstract

Purpose: Insomnia, parasomnia, and obstructive sleep apnea have been associated with a number of disease pathologies, but little is known about the relationship of these sleep disorders and cancer. The study explored the risk of sleep disorder (SD)-induced cancer using nationwide population data. Two million data from the National Health Insurance system of Taiwan was used to assess for the relationship.

Patients and Methods: Patients with cancer as our cases and patients without cancer as our control group in 2001-20011. The study patients were traced back to seek the exposure risk factor of sleep disorders, which was divided into three categories: insomnia, obstructive sleep apnea (OSA) and parasomnia. Patients were selected excluding patients who had cancer prior to presenting with the sleep disorder and the person-year is less than 2 years. Each case was randomly matched with two cases with the same age, gender, and index year.

Results: There were significantly increased risks of breast cancer in the patients with insomnia (AHR=1.73; 95% CI: 1.57-1.90), patients with parasomnia (AHR=2.76; 95% CI: 1.53-5.00), and patients with OSA (AHR=2.10; 95% CI: 1.16-3.80). Moreover, patients with parasomnia had significantly higher risk of developing oral cancer (AHR=2.71; 95% CI: 1.02-7.24) compared with patients without parasomnia. The risk of suffering from nasal cancer (AHR=5.96, 95% CI: 2.96-11.99) and prostate cancer (AHR=3.69, 95% CI: 1.98- 6.89) in patients with OSA was significantly higher than that of patients without OSA.

Conclusions: Our findings provided the evidence that people diagnosed with insomnia, parasomnia and OSA are at a higher risk of developing cancers to remind people to improve sleep quality.

KEYWORDS

insomnia, parasomnia, obstructive sleep apnea, cancer

Title

Risk of Cancer in Patients with Insomnia, Parasomnia, and Obstructive Sleep Apnea: A Nationwide Nested Case-Control Study

Author

Hui-Feng Fang,1 Nae-Fang Miao,2 Chi-Dan Chen,3 Trevor Sithole,4,5 and Min-Huey Chung6,✉

Publish date

2015;

PMID

29546316

Abstract

Context
Abnormal fatty acid (FA) metabolism contributes to diabetes and cardiovascular disease. The FA receptor CD36 has been linked to risk of metabolic syndrome. In rodents CD36 regulates various aspects of fat metabolism, but whether it has similar actions in humans is unknown. We examined the impact of a coding single-nucleotide polymorphism in CD36 on postprandial hormone and bile acid (BA) responses.

Objective
To examine whether the minor allele (G) of coding CD36 variant rs3211938 (G/T), which reduces CD36 level by ∼50%, influences hormonal responses to a high-fat meal (HFM).

Design
Obese African American (AA) women carriers of the G allele of rs3211938 (G/T) and weight-matched noncarriers (T/T) were studied before and after a HFM.

Setting
Two-center study.

Participants
Obese AA women.

Intervention
HFM.

Main Outcome Measures
Early preabsorptive responses (10 minutes) and extended excursions in plasma hormones [C-peptide, insulin, incretins, ghrelin fibroblast growth factor (FGF)19, FGF21], BAs, and serum lipoproteins (chylomicrons, very-low-density lipoprotein) were determined.

Results
At fasting, G-allele carriers had significantly reduced cholesterol and glycodeoxycholic acid and consistent but nonsignificant reductions of serum lipoproteins. Levels of GLP-1 and pancreatic polypeptide (PP) were reduced 60% to 70% and those of total BAs were 1.8-fold higher. After the meal, G-allele carriers displayed attenuated early (−10 to 10 minute) responses in insulin, C-peptide, GLP-1, gastric inhibitory peptide, and PP. BAs exhibited divergent trends in G allele carriers vs noncarriers concomitant with differential FGF19 responses.

Conclusions
CD36 plays an important role in the preabsorptive hormone and BA responses that coordinate brain and gut regulation of energy metabolism.

Title

CD36 Modulates Fasting and Preabsorptive Hormone and Bile Acid Levels

Author

Cyndya A Shibao,1 Jorge E Celedonio,1 Robyn Tamboli,3 Reem Sidani,3 Latisha Love-Gregory,2 Terri Pietka,2 Yanhua Xiong,3 Yan Wei,3,4 Naji N Abumrad,3 Nada A Abumrad,2 and Charles Robb Flynn3

Publish date

2018 May

PMID

21201579

Abstract

In the title compound, [Ni(C22H26N2O2)]·CH3OH·CHCl3, the NiII ion is in a slightly distorted square-planar geometry involving an N2O2 atom set of the tetra­dentate Schiff base ligand. The asymmetric unit contains one mol­ecule of the complex and one mol­ecule each of chloro­form and methanol. The methanol mol­ecule is hydrogen bonded to the phenolate O atoms. In the crystal structure, short inter­molecular distances between the centroids of six-membered chelate rings [3.7002 (9) a] indicate the presence of π-π inter­actions, which link the mol­ecules into stacks along the a axis. In addition, there are Ni⋯Ni distances which are shorter than the sum of the van der Waals radii of two Ni atoms. The crystal structure is further stabilized by inter­molecular O—H⋯O and C—H⋯O hydrogen bonds, and weak inter­molecular C—H⋯π inter­actions linking mol­ecules into extended one-dimensional chains along the c axis.

Title

{4,4′,5,5′-Tetra­methyl-2,2′-[1,1′-(ethane-1,2-diyldinitrilo)diethyl­idyne]diphenolato}nickel(II)-methanol-chloro­form (1/1/1)

Author

Hoong-Kun Funa,* and Reza Kiaa,‡

Publish date

2008 Sep 1